SANA Sana Biotechnology, Inc.

8-K Current Report

Filed: March 3, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Sana Biotechnology, Inc. (SANA) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 financial results announced March 3, 2026
• Actual figures in Exhibit 99.1 press release — key metrics not disclosed in this filing item

Item 8.01 · Other Events

• ATM offering expanded: new S-3 filed for up to $150M in common stock sales via TD Cowen as agent
• Prior ATM (May 2025) sold ~11.3M shares for ~$45.8M net proceeds; ~$71.6M of prior capacity unused but now superseded

+3 more insights

Get deeper insights on Sana Biotechnology, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.